Influenza A virus H5N1 vaccine - Antigen Express

Drug Profile

Influenza A virus H5N1 vaccine - Antigen Express

Alternative Names: AE 443p; AE AI vaccine; H5N1 virus vaccine - Antigen Express; H5N1 virus vaccine - Generex Biotechnology; Influenza peptide vaccines - Antigen Express; Pandemic influenza virus vaccine - Antigen Express/University of Rochester

Latest Information Update: 08 Feb 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Antigen Express
  • Class Influenza A virus H5N1 vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase I Influenza A virus H5N1 subtype

Most Recent Events

  • 08 Feb 2017 Influenza A virus H5N1 vaccine - Antigen Express is available for licensing as of 08 Feb 2017. (Antigen Express pipeline, February 2017)
  • 03 Mar 2008 Generex Biotechnology has extended its agreement with the Lebanese-Canadian Hospital for follow-on testing of specific H5N1 vaccine peptides
  • 22 Aug 2007 Antigen Express enters into an agreement with the University of Rochester to help develop an avian influenza virus vaccine
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top